The effect of cyproheptadine on plasma growth hormone (GH) and on somatostatin response to GH-releasing hormone in man
| Autor: | R H Rosskamp, F. Haverkamp, G von Kalckreuth |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Clinical Biochemistry Cyproheptadine Radioimmunoassay Neuropeptide Administration Oral Peptide hormone Growth Hormone-Releasing Hormone Biochemistry Endocrinology Oral administration Internal medicine Blood plasma medicine Humans Chemistry Biochemistry (medical) General Medicine Somatostatin Growth Hormone Female Hormone medicine.drug |
| Zdroj: | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 22(5) |
| ISSN: | 0018-5043 |
| Popis: | Cyproheptadine (CPH)--a putative serotonin antagonist--is known to inhibit growth hormone (GH) response to various pharmacological stimuli, as well as during sleep. To elucidate the possible site at which this drug takes effect, we examined plasma GH and somatostatin response to i.v. GHRH1-44 (1 microgram/kg body wt.) before and after CPH treatment in 10 healthy volunteers. The oral administration of CPH (8-12 mg daily for 5 days; total dose 56 mg) significantly curbed GH response to GHRH as expressed in peak plasma GH values (32.0 +/- 6.1 micrograms/l vs. 12.6 +/- 3.2 micrograms/l; P less than 0.01) and in integrated GH response area (2368 +/- 517 micrograms x l-1 x 2 h vs. 744 +/- 172 micrograms x l-1 x 2 h; P less than 0.01). Plasma somatostatin levels did not change in response to GHRH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|